|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trephination mini-craniectomy for traumatic posterior fossa epidural hematomas in selected pediatric patients显示文摘以后的窝硬膜上的 hematomas (PFEDH ) 在孩子是不平常的,但是通常由于威胁生活的 brainstem 压缩的风险要求及时外科的干预。我们试图由与回顾地考察的 trephination mini-craniectomy.MethodsWe 对待选择小儿科的病人使外科的过程更少侵略从2010年1月为创伤的 PFEDH 在我们的部门被对待到2015年1月 .ResultsDuring 的小儿科的病人的临床的功课,放射学的调查结果,外科的过程,和预测这个时期, 17 个病人的一个总数通过手术为 PFEDH 被对待, 7 为 hemato 与 trephination 微型部分颅骨切除术被管理结果在与格拉斯哥结果 20 评估了的所有 7 个病人好。在这个系列没有死亡。平均 30 月的临床的后续证明没有 complications.ConclusionOur 结果,病人们经历了令人满意的恢复建议 trephination 微型部分颅骨切除术是为有中等 hematoma 的选择 PFEDH 病人的一种安全外科的技术体积和稳定的神经病学的功能。然而,标准部分颅骨切除术是当在神经病学的功能或 hematomas 是的病人有快速的恶化时,推荐大、施加的严重集体效果。 | Han-Song Sheng Chao-Guo You Liang Yang Nu Zhang Jian Lin Fen-Chun Lin Mao-De Wang | 2017 | Chinese Journal of Traumatology2017，20，4： | 5 |
| 2 | Successful treatment of pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii with multi-route tigecycline: A case report显示文摘BACKGROUND Pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii(A.baumannii)is one of the most severe complications associated with craniotomy.However,limited therapeutic options exist for the treatment of A.baumannii ventriculitis due to the poor penetration rate of most antibiotics through the blood-brain barrier.CASE SUMMARY A 68-year-old male patient with severe traumatic brain injury developed pyogenic ventriculitis on postoperative day 24 caused by extensively drug-resistant A.baumannii susceptible to tigecycline only.Successful treatment was accomplished through multi-route administration of tigecycline,including intravenous combined with continuous ventricular irrigation plus intraventricular administration.The pus was cleared on the 3rd day post-irrigation,and cerebrospinal fluid cultures were negative after 12 d.CONCLUSION Our findings suggest that multi-route administration of tigecycline can be a therapeutic option against pyogenic ventriculitis caused by extensively drugresistant A.baumannii. | Wei Li Dan-Dong Li Bo Yin Dong-Dong Lin Han-Song Sheng Nu Zhang | 2021 | World Journal of Clinical Cases2021，9，3： | 2 |
| 3 | Phase Ⅱ trial of lapatine for brain metastases in patients with human epidermal growth factor receptor-2 positive with breast cancer 显示文摘 | Lin NU Carey LA Liu MC | 2008 | J Clin Oncol2008，26，12： | 1 |
| 4 | Phase Ⅱ trial of lapa- tinib for brain metastases in patients with HER2-positive breast cancer显示文摘 | Lin NU Carey LA Liu MC | 2006 | J Clin Oncol2006，24，318： | 1 |
| 5 | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? 显示文摘 | Vaz-Luis I Winer EP Lin NU | 2013 | Ann Oneol2013，24，2： | 1 |
| 6 | EGF105084, a phase Ⅱ study of lapatinib for brain metastases in patients with HER2 breast cancer following trastuzumab-based systemic therapy and cranial radiotherapy 显示文摘 | Lin NU Dieras V Paul D | 2007 | Breast Cancer Res Treat2007，106，2721： | 1 |
| 7 | Dose density in breast cancer: A simple message? 显示文摘 | Lin NU Gelman R Winer EP | 2005 | J Natl Cancer Inst2005，97，23： | 1 |
| 8 | Brain metastases: the HER2 paradigm 显示文摘 | Lin NU Winer EP | 2007 | Clin Cancer Res2007，13，6： | 1 |
| 9 | Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease, results from CALGB 9342显示文摘 | Harris LN Breadwater G Lin NU | 2006 | Breast Cancer Res2006，8，6： | 1 |
| 10 | Evaluation of response to lapatinib in patients with HER2-positive metastatic breast cancer using FDGPET 显示文摘 | van den Abbeele AD Lin NU Yap JT | 2006 | Breast Cancer Res Treat2006，100，67681： | 1 |
| 11 | Muhicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer显示文摘 | Lin NU Di6ras V Paul D | 2009 | Clin Cancer Res2009，15，4： | 1 |
| 12 | Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer 显示文摘 | Lin NU Carey LA Liu MC | 2008 | J Clin Oneol2008，26，12： | 1 |
| 13 | Multicenter phase Ⅱ studyof lapatinib in patients with brain metastases from HER-2 positivebreast cancer显示文摘 | Lin NU Diéras V Paul D | | 0，，04： | 1 |
| 14 | A phase I1 study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2- positive metastatic breast cancer progressing after trastuzumab显示文摘 | LIN NU WINER EP WHEATLEY D et d | 2012 | Breast Cancer Res Treat2012，133，3： | 1 |
| 15 | Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review显示文摘 | Chen RC Lin NU Golshan M | 2008 | J Clin Oncol2008，26，49： | 1 |
| 16 | Sites of distant recurrence and clinical outcomes in patients with metastatic triple- negative breast cancer: high incidence of central nervous system metastases显示文摘 | Lin NU Claus E Sohl J | 2008 | Cancer2008，113，10： | 1 |
| 17 | Multicenter phase Ⅱ study of lapatinib in patients with brain metastases from HER2 positive breast cancer显示文摘 | LIN NU DIERAS V PAUL D | 2009 | Clin Cancer Res2009，15，2： | 1 |
| 18 | Phase Ⅱ study of CT- 2103 as firstor second-line chemotherapy in patients with meta-static breast cancer: unexpected incidence of hypersensitivity reactions显示文摘 | LIN NU PARKER LM COME SE | 2007 | Invest New Drugs2007，25，4： | 1 |
| 19 | Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease:results from CALGB 9342显示文摘 | HarrisLN BroadwaterG Lin NU | 2006 | Breast Cancer Res2006，8，6： | 1 |
| 20 | Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer显示文摘 | Lin NU Diéras V Paul D | 2009 | Clin Cancer Res2009，15，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员